ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate Partnership agreement with Charlotte FC. The Company intends to use the Associate partnership to build visibility for its brands such as AI Tape which is manufactured locally in the Charlotte area. “We are very excited... Read More

ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate Partnership agreement with Charlotte FC. The Company intends to use the partnership to build visibility for its brands such as AI Tape which is manufactured locally in the Charlotte area. “We are very excited to partner... Read More

ORLANDO, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received the Certificate of Registration from the United States Patent and Trademark Office (USPTO) on Feb 18, 2025, for trademark registration Number 7,692,920, covering the mark "Nutriband™." The Trademark registration covers Goods/Services: Class: 042... Read More

Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments Nutriband is partnering with Kindeva Drug Delivery to develop Aversa™ Fentanyl which combines Nutriband’s Aversa™ abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. ORLANDO, Fla., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc.... Read More

ORLANDO, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced World and European Wrestling Gold medalist and Olympic Silver medalist Anastasia Nichita has been appointed to its Product Advisory Board to expand the Nutriband Brand and promote it’s over the counter sports and consumer products internationally. "We... Read More

ORLANDO, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on February 3, 2025 for patent application 18/369,241, "Abuse and Misuse Deterrent Transdermal Systems" which covers its Aversa™... Read More

ORLANDO, Fla., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders highlighting the company’s achievements in 2024 and the outlook for 2025. Dear Fellow Shareholders, As we close out 2024, I want to extend my deepest gratitude to you, our loyal shareholders, for your continued trust and support. This year has been one... Read More

Nutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband is targeting to file for FDA approval for AVERSA™ Fentanyl in the first half of 2025. ORLANDO, Fla., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that... Read More

ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its financial results for the third quarter ended October 31, 2024. The Company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fentanyl, with an NDA submission targeted for first half of 2025. Nutriband is continuing to expand its... Read More

ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (Nasdaq:NTRB)(Nasdaq:NTRBW) today announced that it will be presenting at the Noble Conference taking place December 3rd and 4 th at the Florida Atlantic University in Boca Raton, FL. Company President and Chairman Serguei Melnik will present at 1.30 PM in Conference room 3 on December 4 th to primarily discuss the company’s AVERSA technology. Information about... Read More

ORLANDO, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received a Notice of Publication of the Registration and Grant of a Standard Patent (R) from the Hong Kong Intellectual Property Department for patent application entitled, “Abuse and Misuse Deterrent Transdermal... Read More

ORLANDO, FL / ACCESSWIRE / October 31, 2024 / Nutriband (NASDAQ:NTRB) (NASDAQ:NTRBW), has announced that theChinese National Intellectual Property Administrant (CNIPA) has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™. The patent underpins 4p Therapeutics' abuse deterrent transdermal system, AVERSA, which uses taste aversion to address... Read More

The approved product will be exclusively distributed through Farmavision S.A. throughout Costa Rica ORLANDO, FL / ACCESSWIRE / October 17, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), today announced that it has received approval from the Costa Rica Ministry of Health for the production and marketing of its Mosquito Repellent Patch, designed to reduce the risk of mosquito bites and associated health risks associated... Read More

ORLANDO, FL / ACCESSWIRE / October 2, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is pleased to invite investors to a webinar on October 17, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nutriband Founder and Chief Executive Officer Gareth Sheridan and Founder and President Serguei Melnik, who will share insight into the... Read More

Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products AVERSA... Read More

Nutriband signs trademark licensing agreement for Bitrex® brand denatonium benzoate, the most bitter substance in the world, as an aversive agent for its Aversa™ Fentanyl abuse deterrent fentanyl transdermal patch Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant... Read More

ORLANDO, FL / ACCESSWIRE / September 16, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), has announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of September 16, 2024, the Company had 11,106,185 shares of common stock outstanding. Progress continues on the development of AVERSA Fentanyl, with the Company maintaining its target of submitting an NDA to the FDA in Q1/Q2 2025 About... Read More

ORLANDO, FL / ACCESSWIRE / September 4, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) has reported its financial results for the second quarter ended July 31, 2024. The Company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fentanyl, with an NDA submission targeted for the first half of 2025. Nutriband is expanding its kinesiology tape... Read More

ORLANDO, FL / ACCESSWIRE / July 19, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is pleased to invite investors to a webinar on July 25, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nutriband Chairman and President Serguei Melnik and Chief Executive Officer Gareth Sheridan, who will share insight into the Company's current... Read More

ORLANDO, FL / ACCESSWIRE / July 15, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on July 9, 2024, for trademark application Serial Number 98117984, covering the mark "AVERSA™." The Notice of Allowance signifies that the USPTO is expected to grant a... Read More

ORLANDO, FL / ACCESSWIRE / June 20, 2024 / Nutriband Inc. ("Company") (NASDAQ:NTRB) (NASDAQ:NTRBW) provides an update on its Aversa Fentanyl product development program to shareholders as it aims to complete scale-up of the commercial manufacturing process and move towards the single Phase 1 human abuse potential study prior to NDA filing. As previously reported, the Company with its partner Kindeva Drug Delivery completed... Read More

ORLANDO, FL / ACCESSWIRE / June 3, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), today reported Q1 revenues of $408,532 emphasizing its focus on expanding the company's Kinesiology Tape manufacturing services through its Pocono Pharma subsidiary. The Company has been focused on using penetration pricing to gain a foothold with some of the industry's largest brands and License holders such as KT Tape and Fit For Life... Read More

The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placement ORLANDO, FL / ACCESSWIRE / May 16, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, today announced the appointment of Sergei Glinka to its board of directors. Glinka is a seasoned and highly respected business executive with an impressive track record in leadership... Read More

Private Placement of $8.4 million has closed and will fund the commercial development of lead product AVERSA Fentanyl to NDA filing Nutriband working to complete the commercial scale-up prior to performing the pivotal laboratory assessment and clinical study required for FDA approval AVERSA Fentanyl being developed as 505(b)(2) NDA on single Phase 1 human abuse potential clinical study with no Phase 2 or 3 clinical trials... Read More

ORLANDO, FL / ACCESSWIRE / April 23, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), today announced that following its engagement by Fit For Life Group (FFL), a major brand license holder, on April 19, 2024, the companies fully executed an exclusive Supplier agreement for FFL's new product launch under one of their top brands. Nutriband Inc.'s wholly owned contract manufacturing subsidiary, Active Intelligence, will act... Read More

Nutriband is targeting a 505(b)(2) NDA to the FDA for marketing approval of AVERSA™ Fentanyl in Q1 2025 ORLANDO, FL / ACCESSWIRE / April 19, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of abuse deterrent pharmaceutical products announced that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 2,100,000 shares of common stock... Read More

ORLANDO, FL / ACCESSWIRE / April 1, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) , a pharmaceutical company with a specific focus on transdermal technologies, today announces it has been engaged by and received a first order from Fit For Life Group (FFL), a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband Inc.'s wholly owned contract manufacturing subsidiary, Active... Read More

NDA will be primarily based on a single Phase 1 human abuse potential clinical study with no Phase 2 or 3 clinical trials needed prior to submission. AVERSA™ Fentanyl incorporates Nutriband's Aversa™ abuse-deterrent technology with an FDA-approved fentanyl patch and is being developed via a limited 505(b)(2) New Drug Application (NDA) pathway. ORLANDO, FL / ACCESSWIRE / March 27, 2024 / Nutriband Inc. (NASDAQ:NTRB)... Read More

Data highlights the incidence of abuse and accidental pediatric exposure of transdermal patches containing opioid and stimulant drugs Nutriband's AVERSA™ technology addresses the unmet need for safer abuse-deterrent transdermal patches ORLANDO, FL / ACCESSWIRE / March 25, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today... Read More

ORLANDO, FL / ACCESSWIRE / March 4, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that data on the incidence of transdermal patch abuse and accidental pediatric exposure will be presented at the 2024 American Academy of Pain Medicine (AAPM) Annual Meeting to be held in Scottsdale, Arizona March 7-10, 2024. The... Read More

Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30 th through February 1 st . ORLANDO, FL / ACCESSWIRE / January 29, 2024 / Nutriband Inc. (Nasdaq:NTRB) (Nasdaq:NTRBW) today announced that it will be presenting at the Dealflow Events MicroCap Conference taking place January 30 th through February 1 in Caesars Atlantic City. Company CEO, Gareth Sheridan will make two presentations and answer... Read More

ORLANDO, FL / ACCESSWIRE / January 26, 2024 / Nutriband Inc. ("Company") (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and targets through 2023 and the potential outlook for 2024. The full text of the letter is below. Dear Shareholders, As we wrapped up a successful 2023 and our annual shareholder meeting this week, the entire... Read More

ORLANDO, FL / ACCESSWIRE / January 5, 2024 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today announced it has signed a commercial development and clinical supply agreement for their lead product, Aversa™ Fentanyl, with their partner, Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO) focused on... Read More

ORLANDO, FL / ACCESSWIRE / November 28, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of its new Heating and Cooling Kinesiology Tape as part of its Active Intelligence (AI Tape) Brand portfolio. AI Tape Heating and Cooling provides all of the stretch, support, and benefits of traditional kinesiology tape, plus pain-relieving ingredients... Read More

ORLANDO, FL / ACCESSWIRE / November 8, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), today announced that it has signed a supplier agreement with market leading kinesiology tape company, KT Tape. Nutriband Inc.'s wholly owned contract manufacturing subsidiary, Active Intelligence, will act as manufacturer for a new line of specialized KT tape. Founded in 2008, KT Tape ® has revolutionized the sports medicine industry... Read More

ORLANDO, FL / ACCESSWIRE / October 11, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products, today announced it has completed the market assessment and commercialization strategy for AVERSA™ Buprenorphine, an abuse deterrent buprenorphine transdermal system. The company engaged leading healthcare consulting company Health Advances to assess the market... Read More

Patent issuance expands U.S. patent portfolio for AVERSA™ transdermal abuse deterrent technology ORLANDO, FL / ACCESSWIRE / September 20, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that the United States Patent and Trademark Office (USPTO) has granted US Patent No. 11,759,431 for Nutriband's proprietary AVERSA™ abuse deterrent technology utilizing... Read More

Nominations recognize innovative development of AVERSA™ abuse-deterrent transdermal technology ORLANDO, FL / ACCESSWIRE / September 12, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has been shortlisted for 5 awards at the Pharma Industry Awards 2023 . The Pharma Industry Awards is a long-standing award program for recognizing... Read More

Second quarter 2023 revenues increased 48% compared to second quarter 2022 ORLANDO, FL / ACCESSWIRE / September 11, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the second quarter ended July 31, 2023. Key Highlights: Generated quarterly revenue of $655,928, up 48% over Q2 2022 Revenue for six-months ended July 31,... Read More

AI Tape has potential to tap into the $236 million Elastic Therapeutic Tape market ORLANDO, FL / ACCESSWIRE / August 30, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announces that it has engaged former 6-time Pro-Bowl NFL quarterback, Donovan McNabb as a brand ambassador for its Active Intelligence Tape ("AI Tape") consumer sports recovery tape... Read More

ORLANDO, FL / ACCESSWIRE / July 27, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced the launch of its consumer sports recovery tape brand, Active Intelligence AI Tape ("AI Tape"), with products now available for purchase on Amazon and Activeintell.com . AI Tape is designed to combine many of the traditional benefits of kinesiology tape... Read More

Company targeting FDA submission in the first half of 2024 AVERSA ™ Fentanyl is the flagship product of the Company's AVERSA™ Platform ORLANDO, FL / ACCESSWIRE / July 14, 2023 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has expanded its existing Credit Line facility to $5 Million USD to fund the continued development and regulatory... Read More

ORLANDO, FL / ACCESSWIRE / June 23, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on June 15, 2023 for patent application 17/568,999, "Abuse and Misuse Deterrent Transdermal Systems" which covers its Aversa™ abuse deterrent technology. The receipt of a... Read More

ORLANDO, FL / ACCESSWIRE / May 10, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it will be attending the Biotechnology Innovation Organization (BIO) International Convention taking place June 5-8, 2023, at the Boston Convention & Exhibition Center, in Boston, Massachusetts, USA. The BIO Convention is the premier life sciences networking... Read More

ORLANDO, FL / ACCESSWIRE / April 27, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the fiscal year ended January 31, 2023. Key Highlights: Generated record revenue of $2.1 million, up 46% over the prior fiscal year Successfully obtained court verdict for recovery of shares constituting 15% of its total outstanding... Read More

ORLANDO, FL / ACCESSWIRE / April 19, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a pioneer in the development of innovative transdermal solutions, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 at 08:30 AM (Local Time -PST). Company CEO, Gareth Sheridan will be hosting the presentation and answering questions at the conclusion. To access the live... Read More

ORLANDO, FL / ACCESSWIRE / April 4, 2023 / Nutriband Inc. ("Company") (NASDAQ:NTRB) (NASDAQ:NTRBW) with Kindeva Drug Delivery ("Kindeva") have selected the target AVERSA™ formulation to take forward into commercial scale manufacturing process development for the Company's patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSA™ Fentanyl contains Nutriband's proprietary transdermal... Read More

ORLANDO, FL / ACCESSWIRE / March 28, 2023 / Nutriband Inc. ("Company") (NASDAQ:NTRB) (NASDAQ:NTRBW) has entered into a three-year $2,000,000 Credit Line facility to provide financing through the FDA approval process into commercial scale manufacturing for the Company's patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSA™ Fentanyl contains Nutriband's proprietary transdermal abuse... Read More

ORLANDO, FL / ACCESSWIRE / March 8, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) announced that it has joined Webull's Corporate Communications Service Platform, which will provide Nutriband with a comprehensive suite of investor relations and corporate communications solutions. This will enable Nutriband to enhance its corporate communications efforts, expand its investor outreach, and increase its visibility among... Read More

ORLANDO, FL / ACCESSWIRE / March 2, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that Alan Smith, Ph.D., Chief Operating Officer (COO), Nutriband, and President of its subsidiary, 4P Therapeutics LLC ("4P Therapeutics"), has been selected for the FDA's Center for Research on Complex Generics Stakeholder Expert Committee on Adhesion Testing for Transdermal/Topical Delivery Systems. The... Read More

ORLANDO, FL / ACCESSWIRE / February 15, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that its has completed the requirements to file its application with Ecuador's Health Register (Registro Sanitar Ecuador) to permit the distribution of certain medical devices and cosmetic products in South America. Ecuador is part of the Andean Community CAN. which provides access to four South American countries... Read More

ORLANDO, FL / ACCESSWIRE / January 24, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, today announced details of the Company's participation at the 2023 Transdermal and Microneedle Conference taking place January 23-24, 2023, at the Copthorne Tara Hotel, London, United Kingdom. Gareth Sheridan, Nutriband's CEO, will give a... Read More

Nutriband among the first issuers to dual list on Upstream ORLANDO, FL / ACCESSWIRE / January 5, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, will become available today at 10:00am EST under the ticker symbol NTRB on... Read More

Trading scheduled to Commence on Upstream January 5, 2023 ORLANDO, FL / ACCESSWIRE / December 30, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) announced today that it will be the first company to dual list on Upstream following recent approval. "We are proud to have a trailblazer like Nutriband as the first company to... Read More

ORLANDO, FL / ACCESSWIRE / December 29, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) announced today that it has begun production of its AI Tape brand with an expected launch of the product line in Q1 2023. AI Tape is designed to share many of the benefits of traditional Kinesiology Tape. AI Tape further adds soothing and therapeutic ingredients held in suspension with a proprietary adhesive mix. AI Tape is... Read More

Trading to Commence on Upstream January 5, 2023 under Upstream Ticker Symbol NTRB; all Upstream Participants Eligible to Receive Commemorative NFT ORLANDO, FL / ACCESSWIRE / December 14, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced its approval to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange... Read More

ORLANDO, FL / ACCESSWIRE / December 5, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the third quarter ended October 31, 2022. Key Highlights: Generated record quarterly revenue of $620,000, up 118% over Q3 2021 Revenue for nine-months ended October 31, 2022, was $1,552,074, up 67% year-over-year Continued to... Read More

ORLANDO, FL / ACCESSWIRE / December 2, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announces that Gareth Sheridan, CEO, will be presenting at the RHK Capital Disruptive Growth Conference in New York City on Monday, December 5 at 10:20 AM. Mr. Sheridan will present a corporate overview with a specific focus on the Company's AVERSA technology and market opportunity. The RHK Capital Disruptive Growth Conference... Read More

ORLANDO, FL / ACCESSWIRE / December 1, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) announced that the Canadian Intellectual Property Office (CIPO) has granted Canadian patent No. 2,937,649, entitled "Abuse and Misuse Deterrent Transdermal Systems," with an issue date of November 1, 2022. This patent protects Nutriband's... Read More